Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

NCT06218589 · View on ClinicalTrials.gov ↗

Study Summary

This study aims to test the utility of Velacur ultrasound as a non-invasive, rapid, point of care diagnostic tool for detecting the presence and amount of hepatic steatosis in children and adolescents aged 2 - 20 years.

Interventions

  • DIAGNOSTIC_TEST MRI
  • DIAGNOSTIC_TEST Velacur
  • DIAGNOSTIC_TEST Blood sample collection for biomarkers
  • DIAGNOSTIC_TEST Liver biopsy

Study Locations (2)

Georgia

  • Children's Healthcare of Atlanta (CHOA) — Atlanta
  • Emory Children's Center — Atlanta

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-01-18
Est. Completion 2026-01-31
Phase NA

Sponsor

Emory University

1,434 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06218589

The ClinicalTrials.gov registry entry for NCT06218589 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,434 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Metabolic Dysfunction Associated Steatotic Liver Disease appearing as the primary indexed condition, and to 4 interventions — of which MRI is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06218589 reports 2 study locations spanning 1 distinct geographic area — top geographies include Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06218589 about?

NCT06218589 is a clinical study titled "Non-Invasive Diagnostic Tests for MASLD in Pediatric Population". This study aims to test the utility of Velacur ultrasound as a non-invasive, rapid, point of care diagnostic tool for detecting the presence and amount of hepatic steatosis in children and adolescents aged 2 - 20 years.

What is the current status of trial NCT06218589?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-01-18. Estimated completion is 2026-01-31.

What conditions does trial NCT06218589 study?

This clinical trial studies the following conditions: Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06218589?

The interventions under investigation include: MRI (DIAGNOSTIC_TEST), Velacur (DIAGNOSTIC_TEST), Blood sample collection for biomarkers (DIAGNOSTIC_TEST), Liver biopsy (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06218589?

This trial is sponsored by Emory University, which has 1,434 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06218589 being conducted?

This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial